Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: QTORIN 3.9% rapamycin anhydrous gel Clear all
Active, not recruiting Phase 3 Interventional

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480
View directory record Official record
Conditions
Microcystic Lymphatic Malformation
Interventions
QTORIN 3.9% Rapamycin Anhydrous Gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 4, 2026, 10:10 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

NCT05643872
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
PTX-022
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Brighton, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 4, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 4, 2026, 10:10 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842
View directory record Official record
Conditions
Cutaneous Venous Malformations
Interventions
QTORIN 3.9% rapamycin anhydrous gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 4, 2026, 10:10 AM EDT